Literature DB >> 6556071

Interaction of human plasma kallikrein and its light chain with C1 inhibitor.

F van der Graaf, J A Koedam, J H Griffin, B N Bouma.   

Abstract

The light chain of human plasma kallikrein contains the enzymatic active site. The inactivation of kallikrein and of its isolated light chain by C1 inhibitor was investigated to assess the functional contributions of the heavy-chain region of kallikrein and of high molecular weight kininogen to this reaction. The second-order rate constants for the inactivation of kallikrein or its light chain were respectively 2.7 X 10(6) and 4.0 X 10(6) M -1 min -1. High molecular weight kininogen did not influence the rate of kallikrein inactivation. The nature of the complexes formed between kallikrein or its light chain and C1 inhibitor was studied by using sodium dodecyl sulfate (SDS) gradient polyacrylamide slab gel electrophoresis. Kallikrein as well as its light chain combined with C1 inhibitor to form stable stoichiometric complexes that were not dissociated by SDS and that exhibited apparent molecular weights (Mr's) of 185 000 and 135 000, respectively, on nonreduced SDS gels. Reduction of the kallikrein-C1 inhibitor complex gave a band at Mr 135 000 that comigrated with the complex seen for the light chain-C1 inhibitor complex. During the inactivation of both kallikrein and its light chain, a Mr 94 000 fragment of C1 inhibitor was formed which was unable to inactivate or bind kallikrein or its light chain. Kallikrein inactivated by diisopropyl phosphofluoridate did not form SDS-stable complexes with C1 inhibitor. These results demonstrate that the functional binding site for C1 inhibitor is localized in the light chain of kallikrein.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6556071     DOI: 10.1021/bi00289a037

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  9 in total

1.  alpha(1)-Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1.

Authors:  Thomas Sulikowski; Bryan A Bauer; Philip A Patston
Journal:  Protein Sci       Date:  2002-09       Impact factor: 6.725

2.  Regulation of factor XIa activity by platelets and alpha 1-protease inhibitor.

Authors:  P N Walsh; D Sinha; F Kueppers; F S Seaman; K B Blankstein
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

3.  Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients.

Authors:  B L Zuraw; J G Curd
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

4.  An analysis of the contact phase of blood coagulation: effects of shear rate and surface are intertwined.

Authors:  K Gregory; D Basmadjian
Journal:  Ann Biomed Eng       Date:  1994 Mar-Apr       Impact factor: 3.934

5.  Autoantibody facilitated cleavage of C1-inhibitor in autoimmune angioedema.

Authors:  J Jackson; R B Sim; K Whaley; C Feighery
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

6.  Proteolytic inactivation of plasma C1- inhibitor in sepsis.

Authors:  J H Nuijens; A J Eerenberg-Belmer; C C Huijbregts; W O Schreuder; R J Felt-Bersma; J J Abbink; L G Thijs; C E Hack
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

7.  Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils.

Authors:  E Eldering; C C Huijbregts; J H Nuijens; A J Verhoeven; C E Hack
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

8.  A common neoepitope is created when the reactive center of C1-inhibitor is cleaved by plasma kallikrein, activated factor XII fragment, C1 esterase, or neutrophil elastase.

Authors:  A de Agostini; P A Patston; V Marottoli; S Carrel; P C Harpel; M Schapira
Journal:  J Clin Invest       Date:  1988-08       Impact factor: 14.808

9.  Complement C1 esterase inhibitor levels linked to infections and contaminated heparin-associated adverse events.

Authors:  Zhao-Hua Zhou; Trina Chen; Kamalpreet Arora; Kenneth Hyams; Steven Kozlowski
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.